Skip to content

Upstream Bio, Inc.

UPB· NasdaqCore metricsCIK 2022626

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -10.50%
Market cap
$156.49M
54.81M shares
Filings
137
$395.00K
Q3 2026+20.4% FY25 yoy
-$41.19M
Q3 2026N/M FY25 yoy
-$43.38M
Q3 2026N/M FY25 yoy
-$137.70M
Q3 2026derivedN/M FY25 yoy
-$0.75
Q3 2026N/M FY25 yoy
$47.42M
Q3 2026−68.8% FY25 yoy
$156.49M
—
54.5×
0.7×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$2.8687.96%$20.87past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.85MFY 2025
$2.85M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,854,000reported
FY 20242024-12-31$2,370,000reported
FY 20232023-12-31$2,380,000reported

Pharmaceutical preparations

Upstream Bio, Inc. is the 196th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Upstream Bio, Inc. · CIK 2022626 · Engraved from SEC EDGAR